Search 

Ananda Devices is a biotech company specialized in in vitro assay developments. Leveraging our proprietary nano-organization technology, we have developed physiologically relevant in vitro models that generate predicative responses early on in the compound development processes, thereby accelerating compound discovery and de-risking key developmental investments.
Our nervous on-a-chip technology enables clients to perform drug screening, toxicity and efficacy testing up to 50x faster and 90% more cost-effective. We have 20+ years of experience in neuroscience and tissue engineering, and we have been a developer of unique devices to grow brain, spinal cord and innervated skin models for clients in 12 countries.

Our product:
NeuroHTSTM is a first-in-class high throughput screening (HTS) platform to rapidly cultivate over 3,000 CNS or PNS neurons/plate into physiologically relevant networks.
Its easy-to-use technology requires no additional equipment such as shakers and tubing.
It is compatible with most automation solutions, suitable for both and human/animal models

Our customized services:
Our core technology enables 4 types of innovative assay developments:
-Organization of cell and tissue types for reproducible and physiologically relevant in vitro testing
-Innervation of different tissues
-Miniaturization of existing models to increase throughput and sensitivity
-Development of complex co-culture models to mimic disease on-a-chip

Assist Consultation, Assistance, Service
• Identify Distribution Opportunities, Partners, Joint Ventures
• Guidance for Product Registration (SFDA), Regulatory Issues
• Intellectual Property Assessment
• Develop Successful Business Strategy
• Marketing/Analysis
• Manufacturing/Sourcing
• Investment Advisory

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

GattaCo develops products that enable fast accurate evidence-based decision making to improve healthcare outcomes. We do this by solving the fundamental problems in sample purification, the most challenging component of the diagnostic testing workflow.

 Our new Plasm™ Module is a revolutionary, patented, automatic plasma separation and metering module or insert used to provide high-purity, metered plasma to a rapid diagnostic testing platform, such as lateral flow, biosensor, or other Point of Care (POC) device, from finger-stick capillary blood. The initial version of the Plasm Module is optimized for antibody testing and will revolutionize POC diagnostics by improving: 

• Sensitivity: Increased number of antibodies compared to the same volume of whole blood.
• Specificity Accuracy: High quality/purity sample with reduced background.
• Repeatability: Plasma is metered to +/- 5%.
Quantitation: Precisely metered output, independent of hematocrit.

Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.

In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.